Patents by Inventor Stefan Dengl

Stefan Dengl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10538585
    Abstract: Herein are reported anti-ANG2 antibodies. A specific anti-ANG2 antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 20, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 21, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 23.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: January 21, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Peter Michael Huelsmann, Hubert Kettenberger, Joerg Moelleken, Michael Molhoj, Joerg Thomas Regula
  • Patent number: 10517945
    Abstract: Herein is reported a conjugate comprising an antigen and an antibody that specifically binds to the antigen wherein a covalent bond is formed between the antigen and an amino acid residue in the CDR2 of the antibody, an antibody comprising a cysteine residue at amino acid position 53 (according to Kabat) in the heavy chain CDR2 and uses thereof.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: December 31, 2019
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Joerg Benz, Ulrich Brinkmann, Stefan Dengl, Sebastian Dziadek, Guy Georges, Michael Grote, Alexander Haas, Eike Hoffmann
  • Patent number: 10519249
    Abstract: Herein is reported a conjugate of a haptenylated polypeptide toxin and an anti-hapten antibody, wherein a disulfide bond is formed between a cysteine residue either before or after the lysine residue that is used for hapten-conjugation and a cysteine residue in the CDR2 of the antibody, whereby the CDR2 is determined according to Kabat.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: December 31, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Eike Hoffmann, Stefan Dengl, Klaus Mayer
  • Publication number: 20190389971
    Abstract: Herein is reported a circular fusion polypeptide comprising a first part of a binding domain, a second part of a binding domain and a spacer domain, wherein the spacer domain is a polypeptide and comprises at least 25 amino acid residues, the first part of the binding domain is a polypeptide and is fused via a first linker to the N-terminus of the spacer domain, the second part of the binding domain is a polypeptide and is fused via a second linker to the C-terminus of the spacer domain, the first part of the binding domain and the second part of the binding domain are associated with each other and form a binding site that specifically binds to a target.
    Type: Application
    Filed: November 1, 2018
    Publication date: December 26, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Friederike Hesse, Sabine Imhof-Jung, Josef Platzer
  • Publication number: 20190382489
    Abstract: The present invention relates to anti-PD1 antibodies and methods of using the same.
    Type: Application
    Filed: December 18, 2018
    Publication date: December 19, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: JOERG BENZ, LAURA CODARRI DEAK, STEFAN DENGL, SEBASTIAN FENN, JENS FISCHER, GUY GEORGES, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, OLIVER PLOETTNER, STEFAN SEEBER, BARBARA WEISER, ILDIKO WUENSCHE, ADRIAN ZWICK
  • Patent number: 10434184
    Abstract: The invention provides anti-TPBG antibodies and methods of using the same.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: October 8, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Sebastian Fenn, Jens Fischer, Thomas Friess, Sabine Imhof-Jung, Ben-Fillippo Krippendorff, Christian Schantz, Tilman Schlothauer, Claudio Sustmann, Barbara Weiser, Adrian Zwick
  • Patent number: 10407511
    Abstract: Herein is reported a conjugate comprising a helicar motif amino acid sequence containing compound and an antibody that specifically binds to the helicar motif amino acid sequence characterized by a covalent bond between the helicar motif amino acid sequence containing compound and an amino acid residue in the CDR2 of the anti-helicar antibody, whereby the CDR2 is determined according to Kabat.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: September 10, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Guy Georges, Eike Hoffmann, Georg Tiefenthaler, Ekkehard Moessner, Stefan Dengl, Achim Gaertner
  • Publication number: 20190241661
    Abstract: Herein is reported a method for determining complement dependent cytotoxicity of a composition comprising i) a first binding site that specifically binds to a first epitope on a first antigen, which is conjugated to a first Fc-region polypeptide of human origin, and ii) a second binding site that specifically binds to a second epitope on a second antigen, which is conjugated to a second Fc-region polypeptide of human origin, wherein the method comprises the steps of incubating a cell expressing the first antigen and the second antigen with the composition and a mixture of anti-mCRP antibodies; adding normal human serum or rabbit complement to the mixture; and determining cell lysis and thereby determining complement dependent cytotoxicity of the composition.
    Type: Application
    Filed: December 13, 2018
    Publication date: August 8, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Sonja Offner
  • Publication number: 20190218282
    Abstract: Herein is reported a recombinant fusion polypeptide comprising an antibody heavy chain variable domain, a multimerization domain and an antibody light chain variable domain, wherein the antibody heavy chain variable domain is fused (either directly or via a first (peptidic) linker) to one terminus of the multimerization domain, the antibody light chain variable domain is fused (either directly or via a second (peptidic) linker) to the respective other terminus of the multimerization domain, and the antibody heavy chain variable domain or the antibody light chain variable domain has a (intra-peptidic) disulphide bond to the multimerization domain.
    Type: Application
    Filed: December 20, 2018
    Publication date: July 18, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: STEFAN DENGL, PETER MICHAEL HUELSMANN
  • Patent number: 10344085
    Abstract: Herein are reported humanized anti-IL-1beta antibodies that are humanized variants of the murine anti-IL-1beta antibody H34. A specific humanized antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 25, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 27, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 28.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: July 9, 2019
    Assignee: Hoffman-La Roche, Inc.
    Inventors: Stefan Dengl, Peter Michael Huelsmann, Christian Gassner, Sebastian Breuer, Olaf Mundigl, Guy Georges, Ralf Schumacher, Guido Hartmann, Sabine Gruener
  • Patent number: 10323089
    Abstract: Herein is reported an anti-transferrin receptor antibody that specifically binds to human transferrin receptor and cynomolgus transferrin receptor, which comprises i) a humanized heavy chain variable domain derived from the heavy chain variable domain of SEQ ID NO: 01, and ii) a humanized light chain variable domain derived from the light chain variable domain of SEQ ID NO: 26, wherein the antibody has an off-rate for the human transferrin receptor that is equal to or less than (i.e. at most) the off-rate of the anti-transferrin receptor antibody 128.1 for the cynomolgus transferrin receptor, whereby the off-rates are determined by surface plasmon resonance, and whereby the anti-transferrin receptor antibody 128.1 has a heavy chain variable domain of SEQ ID NO: 64 and a light chain variable domain of SEQ ID NO: 65.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: June 18, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Ulrich Goepfert, Jens Niewoehner, Tilman Schlothauer
  • Publication number: 20180311371
    Abstract: The invention provides anti-TPBG antibodies and methods of using the same.
    Type: Application
    Filed: April 27, 2018
    Publication date: November 1, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan DENGL, Sebastian FENN, Jens FISCHER, Thomas FRIESS, Sabine IMHOF-JUNG, Ben-Fillippo KRIPPENDORFF, Christian SCHANTZ, Tilman SCHLOTHAUER, Claudio SUSTMANN, Barbara WEISER, Adrian ZWICK
  • Publication number: 20180282408
    Abstract: Herein is reported an anti-transferrin receptor antibody that specifically binds to human transferrin receptor and cynomolgus transferrin receptor, which comprises i) a humanized heavy chain variable domain derived from the heavy chain variable domain of SEQ ID NO: 01, and ii) a humanized light chain variable domain derived from the light chain variable domain of SEQ ID NO: 26, wherein the antibody has an off-rate for the human transferrin receptor that is equal to or less than (i.e. at most) the off-rate of the anti-transferrin receptor antibody 128.1 for the cynomolgus transferrin receptor, whereby the off-rates are determined by surface plasmon resonance, and whereby the anti-transferrin receptor antibody 128.1 has a heavy chain variable domain of SEQ ID NO: 64 and a light chain variable domain of SEQ ID NO: 65.
    Type: Application
    Filed: December 19, 2017
    Publication date: October 4, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Ulrich Goepfert, Jens Niewoehner, Tilman Schlothauer
  • Patent number: 10087246
    Abstract: Herein are reported anti-PDGF-B antibodies and their use in ophthalmology.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: October 2, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Marc Bedoucha, Sebastian Breuer, Stefan Dengl, Christian Gassner, Guy Georges, Sabine Gruener, Guido Hartmann, Peter Michael Huelsmann, Joerg Moelleken, Olaf Mundigl, Joerg Thomas Regula, Barbara Weiser
  • Publication number: 20180079804
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Application
    Filed: December 5, 2017
    Publication date: March 22, 2018
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • Patent number: 9862763
    Abstract: The invention provides humanized anti-human Tau(pS422) antibodies and methods of using the same.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: January 9, 2018
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Thomas Emrich, Guy Georges, Ulrich Goepfert, Fiona Grueninger, Adrian Hugenmatter, Anton Jochner, Hubert Kettenberger, Joerg Moelleken, Ekkehard Moessner, Olaf Mundigl, Jens Niewoehner, Tilman Schlothauer, Michael Molhoj, Kevin Brady
  • Publication number: 20170342128
    Abstract: Herein is reported a method for the production of a polypeptide that is biologically active as n-mer comprising a nucleic acid encoding a fusion polypeptide according to the following formula (Bn-CSo-Is-CSp-FC-CSq-ItCSr-Bm)u, wherein B denotes a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region, FC denotes a heavy chain Fc-region polypeptide, CS denotes a cleavage site, and I denotes an intervening amino acid sequence, wherein FC does not substantially bind to an Fc-receptor, recovering the fusion polypeptide from the cell or the cultivation medium, optionally cleaving the fusion polypeptide with a protease, and thereby producing a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region.
    Type: Application
    Filed: May 9, 2017
    Publication date: November 30, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Johannes Auer, Martin Bader, Stefan Dengl, Stefan Lorenz, Stefan Seeber
  • Publication number: 20170247447
    Abstract: Herein are reported humanized anti-IL-1beta antibodies that are humanized variants of the murine anti-IL-1beta antibody H34. A specific humanized antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 25, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 27, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 28.
    Type: Application
    Filed: May 9, 2017
    Publication date: August 31, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Peter Michael Huelsmann, Christian Gassner, Sebastian Breuer, Olaf Mundigl, Guy Georges, Ralf Schumacher, Guido Hartmann, Sabine Gruener
  • Publication number: 20170247441
    Abstract: Herein are reported anti-ANG2 antibodies. A specific anti-ANG2 antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 29, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 30, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 32.
    Type: Application
    Filed: May 10, 2017
    Publication date: August 31, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Peter Michael Huelsmann, Hubert Kettenberger, Joerg Moelleken, Michael Molhoj, Joerg Thomas Regula
  • Publication number: 20170247440
    Abstract: Herein are reported anti-PDGF-B antibodies and their use in ophthalmology.
    Type: Application
    Filed: May 9, 2017
    Publication date: August 31, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marc Bedoucha, Sebastian Breuer, Stefan Dengl, Christian Gassner, Guy Georges, Sabine Gruener, Guido Hartmann, Peter Michael Huelsmann, Joerg Moelleken, Olaf Mundigl, Joerg Thomas Regula, Barbara Weiser